Princeton, NJ - Advaxis, Inc., a clinical-stage cancer immunotherapy company, today announced the pricing of its previously announced underwritten public offering of 2,800,000 shares of its common stock at a public offering price of $19.00 per share. Advaxis has also granted the underwriters a 30-day option to purchase up to an additional 420,000 shares of common stock from Advaxis. The gross proceeds to Advaxis from the public offering are expected to be $53.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
The offering is expected to close on May 5, 2015, subject to customary closing conditions. Advaxis intends to use the net proceeds from the public offering to fund its continued research and development initiatives in connection with expanding its product pipeline and for other general corporate purposes.
Jefferies LLC and Barclays Capital Inc. are acting as joint book-running managers for the offering, Guggenheim Securities, LLC is acting as lead manager, and Janney Montgomery Scott LLC, Aegis Capital Corp. and H.C. Wainwright & Co., LLC are acting as co-managers.
The securities described above are being offered by Advaxis pursuant to a "shelf" registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission (SEC) on April 27, 2015. A final prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, by contacting Jefferies LLC, 520 Madison Avenue, 2nd Floor, New York, NY, 10022, Attention: Equity Syndicate Prospectus Department, or by telephone at 877-547-6340, or by email at prospectus_department@jefferies.com or Barclays Capital Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by calling (888) 603-5847 or by emailingBarclaysprospectus@broadridge.com. Investors may also obtain these documents for no charge by visiting the SEC's website at www.sec.gov.
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm-LLO platform technology. The Lm-LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis's lead Lm-LLO immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for a Phase 1/2 immunotherapy study to evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis's ADXS-HPV as a treatment for patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck cancer.
Jefferies LLC and Barclays Capital Inc. are acting as joint book-running managers for the offering, Guggenheim Securities, LLC is acting as lead manager, and Janney Montgomery Scott LLC, Aegis Capital Corp. and H.C. Wainwright & Co., LLC are acting as co-managers.
The securities described above are being offered by Advaxis pursuant to a "shelf" registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission (SEC) on April 27, 2015. A final prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, by contacting Jefferies LLC, 520 Madison Avenue, 2nd Floor, New York, NY, 10022, Attention: Equity Syndicate Prospectus Department, or by telephone at 877-547-6340, or by email at prospectus_department@jefferies.com or Barclays Capital Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by calling (888) 603-5847 or by emailingBarclaysprospectus@broadridge.com. Investors may also obtain these documents for no charge by visiting the SEC's website at www.sec.gov.
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm-LLO platform technology. The Lm-LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis's lead Lm-LLO immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for a Phase 1/2 immunotherapy study to evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis's ADXS-HPV as a treatment for patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck cancer.
